Cargando…

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies

Pemigatinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) family of receptors that is approved for the treatment of cholangiocarcinoma with FGFR2 fusion or other rearrangements. Data from a first‐in‐human clinical study were used to assess the potential for pemigatinib to pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Xiaohua, Ji, Tao, Liu, Xiang, Chen, Xuejun, Yeleswaram, Swamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929369/ https://www.ncbi.nlm.nih.gov/pubmed/34951522 http://dx.doi.org/10.1002/prp2.906

Ejemplares similares

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
por: Gong, Xiaohua, et al.
Publicado: (2023)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
por: Liu, Phillip C. C., et al.
Publicado: (2020)

Pemigatinib for cholangiocarcinoma
Publicado: (2022)

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
por: Fujiwara, Yutaka, et al.
Publicado: (2023)

Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
por: Puar, Akshan, et al.
Publicado: (2022)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
por: Deng, Ting, et al.
Publicado: (2023)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
por: Alekseev, Oleg, et al.
Publicado: (2021)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1(N546K) Mutation
por: Capone, Stephen, et al.
Publicado: (2022)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
por: Bissonnette, Robert, et al.
Publicado: (2022)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
por: Srinivas, Nithya, et al.
Publicado: (2020)

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
por: Chen, Zi-Rong, et al.
Publicado: (2023)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
por: Wadsley, Jonathan, et al.
Publicado: (2023)

A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma
por: Hempel, Louisa, et al.
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2022)

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
por: Merz, Valeria, et al.
Publicado: (2020)

Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
por: Yukutake, Masanobu, et al.
Publicado: (2022)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
por: Pace, Angelica, et al.
Publicado: (2023)

Fibroblast Growth Factor-5 Participates in the Progression of Hepatic Fibrosis
por: Hanaka, Hiromi, et al.
Publicado: (2014)

Cardiac Fibrosis and Cardiac Fibroblast Lineage-Tracing: Recent Advances
por: Fu, Xing, et al.
Publicado: (2020)

Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts
por: YI, XIN, et al.
Publicado: (2014)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Fibroblast Growth Factor–23 and Cardiac Structure and Function
por: Agarwal, Isha, et al.
Publicado: (2014)

Mechanism of fibroblast growth factor 21 in cardiac remodeling
por: Zhao, Zeyu, et al.
Publicado: (2023)

The Fibroblast Growth Factor 9 (Fgf9) Participates in Palatogenesis by Promoting Palatal Growth and Elevation
por: Li, Ruomei, et al.
Publicado: (2021)

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
por: Yeleswaram, Swamy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qm8oejg4f5p3doabv2hbtifoj2